Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:13:03 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:RARE - ULTRAGENYX PHARMACEUTICAL INC - https://www.ultragenyx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RARE - Q12.224.80·36.000.125.00-0.80-3.11,519.237,31614,69025.71  25.95  24.8442.37  18.2918:20:39May 0615 min RT 2¢

Recent Trades - Last 10 of 14690
Time ETExPriceChangeVolume
18:20:39Q25.32-0.4880
16:27:36Q24.91-0.8910
16:27:36Q24.91-0.8910
16:27:36Q25.05-0.7510
16:10:05Q25.00-0.801
16:10:05Q25.00-0.801
16:10:04Q25.00-0.801
16:10:04Q25.00-0.801
16:04:50Q25.00-0.801
16:04:37Q25.00-0.801

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-06 16:30U:RARENews ReleaseUltragenyx to Participate at Bank of America's 2026 Healthcare Conference
2026-05-05 16:01U:RARENews ReleaseUltragenyx Reports First Quarter 2026 Financial Results and Corporate Update
2026-04-29 08:00U:RARENews ReleaseUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
2026-04-24 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-02 08:30U:RARENews ReleaseUltragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
2026-03-30 08:30U:RARENews ReleaseUltragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
2026-03-20 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-03-13 22:16U:RARENews ReleaseUltragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
2026-03-12 08:30U:RARENews ReleaseUltragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
2026-02-23 16:30U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in March
2026-02-23 08:30U:RARENews ReleaseUltragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
2026-02-20 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-02-12 16:01U:RARENews ReleaseUltragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
2026-02-05 16:05U:RARENews ReleaseUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
2026-02-03 08:00U:RARENews ReleaseUltragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Child
2026-01-30 08:30U:RARENews ReleaseUltragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
2026-01-23 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-01-12 07:30U:RARENews ReleaseUltragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
2026-01-07 16:05U:RARENews ReleaseUltragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-30 16:05U:RARENews ReleaseUltragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)